calcimycin and Leukemia--Myelogenous--Chronic--BCR-ABL-Positive

Fulvic acid (FA) was extracted and purified from Canadian Sphagnum peat (CP-FA) and characterized by using an element analysis meter, Fourier transform infrared (FT-IR) spectroscopy, electron spin resonance (ESR) spectroscopy, and (13)C-nuclear magnetic resonance ((13)C-NMR) spectroscopy. To investigate the antiallergic effect of CP-FA, we incubated rat basophilic leukemia (RBL-2H3) cells with 0.001-10.0 microg/ml of CP-FA and determined the beta-hexosaminidase release inhibition at different response stages. The intracellular calcium [Ca(2+)](i) level was also determined by using Fluo 3-AM, a calcium-specific fluorescent probe, and the cytotoxicity of CP-FA was determined by the 3-(4,5-dimethythiazol-2-yl)-2,5-diphenyl-tetrazolium bromide (MTT) assay. The results revealed that RBL-2H3 cells incubated for 48 h with 0.001-10.0 microg/ml of CP-FA did not show any decreased viability. CP-FA inhibited the beta-hexosaminidase release by IgE-sensitized, antigen-stimulated RBL-2H3 cells at the antigen-antibody binding stage and the antibody-receptor binding stage. CP-FA also inhibited histamine release from A23187 plus PMA- or compound 48/80-stimulated KU812 cells. Furthermore, there was a decrease in the intracellular [Ca(2+)](i) level in IgE-sensitized cells incubated with CP-FA and stimulated with antigen. Our results show that CP-FA may be useful for the treatment or prevention of allergic diseases.

Topics: Animals; Anti-Allergic Agents; Antigen-Antibody Complex; Antigens; Basophils; Benzopyrans; beta-N-Acetylhexosaminidases; Calcimycin; Calcium; Cell Line, Tumor; Dose-Response Relationship, Drug; Fluorescent Dyes; Formazans; Histamine Release; Humans; Immunoglobulin E; Ionophores; Leukemia, Basophilic, Acute; Leukemia, Experimental; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Nuclear Magnetic Resonance, Biomolecular; p-Methoxy-N-methylphenethylamine; Plant Extracts; Rats; Spectroscopy, Fourier Transform Infrared; Sphagnopsida; Tetradecanoylphorbol Acetate; Tetrazolium Salts

Elevated leukotriene (LT)C(4) synthase activity was observed in peripheral blood granulocyte suspensions from patients with chronic myeloid leukemia (CML). Magnetic cell sorting (MACS) with CD16 monoclonal antibodies (mAbs), which were used to fractionate granulocytes from CML patients and healthy individuals, yielded highly purified suspensions of CD16(+) neutrophils. The purity of these cell fractions was verified by extensive morphologic examination. Reverse transcriptase-polymerase chain reaction (RT-PCR) analyses, demonstrating the absence of interleukin-4 messenger RNA (IL-4 mRNA), further confirmed the negligible contamination of eosinophils in these fractions. Notably, purified CML CD16(+) neutrophils from all tested patients transformed exogenous LTA(4) to LTC(4). These cells also produced LTC(4 )after activation with ionophore A23187 or the chemotactic peptide fMet-LeuPhe (N-formylmethionyl-leucyl-phenylalanine). Subcellular fractionation revealed that the enzyme activity was exclusively distributed to the microsomal fraction. Expression of LTC(4) synthase mRNA in CML CD16(+) neutrophils was confirmed by RT-PCR. Furthermore, Western blot analyses consistently demonstrated expression of LTC(4) synthase at the protein level in CML CD16(+) neutrophils, whereas expression of microsomal glutathione S-transferase 2 occurred occasionally. Expectedly, LTC(4) synthase activity or expression of the protein could not be demonstrated in CD16(+) neutrophil suspensions from any of the healthy individuals. Instead, these cells, as well as CML CD16(+) neutrophils, transformed LTA(4) to LTB(4). The results indicate that aberrant expression of LTC(4) synthase is a regular feature of morphologically mature CML CD16(+) neutrophils. This abnormality, possibly associated with malignant transformation, can lead to increased LTC(4) synthesis in vivo. Such overproduction may be of pathophysiological relevance because LTC(4 )has been demonstrated to stimulate proliferation of human bone marrow-derived myeloid progenitor cells. (Blood. 2000;95:1456-1464)

Topics: Antigens, CD; Arachidonic Acid; Calcimycin; Glutathione Transferase; Granulocytes; Humans; Immunomagnetic Separation; Interleukin-4; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukotrienes; N-Formylmethionine Leucyl-Phenylalanine; Neutrophils; Receptors, IgG; RNA, Messenger; Subcellular Fractions; Transcription, Genetic

We have previously demonstrated that Ph+ myeloid progenitor cells of patients with chronic myeloid leukemia (CML) can acquire characteristics of mature dendritic cells (DC) following calcium mobilization with calcium ionophore (A23187, CI). In this study we characterize the intracellular signaling pathway by which CI induces the acquisition of DC features in these leukemic cells. CI-induced activation of CML cells is attenuated by the calcineurin phosphatase inhibitor cyclosporin A (CsA) as well as the calmodulin (CaM) antagonist W-7. These cause ablation of both the CI-induced immunophenotypic expression of DC markers and immunostimulatory properties in mixed leukocyte responses (MLR). Minimal blocking effect was observed when Ca(2+)/CaM kinase II (281-301) inhibitor was added to the cultures. These findings suggest a Ca(2+)-dependent mechanism for the CI-induced activation of CML cells into antigen-presenting cells (APC), which is primarily mediated through the CaM/calcineurin pathway.

Topics: Calcimycin; Calcium; Calmodulin; Cyclosporine; Dendritic Cells; Humans; Ionophores; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphocyte Activation; Myeloid Progenitor Cells; Phosphoric Monoester Hydrolases; Sulfonamides

Transport of nontransferrin-bound iron into cells is thought to be mediated by a facilitated mechanism involving either the trivalent form Fe(III) or the divalent form Fe(II) following reduction of Fe(III) at the cell surface. We have made use of the probe calcein, whose fluorescence is rapidly and stoichiometrically quenched by divalent metals such as Fe(II), Cu(II), Co(II), and Ni(II) and is minimally affected by variations in ionic strength, Ca(II) and Mg(II). Addition of Fe(II) salts to calcein-loaded human erythroleukemia K-562 cells elicited a slow quenching response that was markedly accelerated by the ionophore A-23187 and was reversed by membrane-permeant but not by impermeant chelators. These observations were confirmed by fluorescence imaging of cells. Other divalent metals such as Co(II), Ni(II), and Mn(II) permeated into cells at roughly similar rates, and their uptake, like that of Fe(II), was blocked by trifluoperazine, bepridil, and impermeant sulfhydryl-reactive organomercurials, indicating the operation of a common transport mechanism. This method could provide a versatile tool for studying the transport of iron and other transition metals into cells.

Topics: Biological Transport; Calcimycin; Cations; Cations, Divalent; Cell Line; Fluoresceins; Fluorescent Dyes; Humans; Iron; Kinetics; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Metals; Pentetic Acid; Tumor Cells, Cultured

The effects of various compounds which modulated the intracellular signal transduction on the induction of class I major histocompatibility complex (MHC) antigens by recombinant human interferon-gamma (rIFN-gamma) were investigated using K562, chronic myelogenous leukemia cells. Class I or class II MHC antigens were not expressed in untreated K562 cells and rIFN-gamma (600 units/ml) weakly induced class I antigens on the cells. Among the compounds tested, verapamil but not the calcium ionophore A23187 enhanced the rIFN-gamma-induced class I antigen expression at both the surface molecule and mRNA levels and enhancement by verapamil occurred in a dose-dependent manner at non-toxic concentrations examined (approximately 50 microM). Verapamil alone had no inducible effect on MHC antigen expression. Deprivation of Ca2+ in culture medium by ethylene glycol-bis(beta-aminoethyl ether) N,N,N',N'-tetraacetic acid (EGTA) could not cause an enhancement of class I antigen induction by rIFN-gamma. Simultaneous exposure of K562 cells to rIFN-gamma (600 units/ml) and recombinant human tumor necrosis factor (rTNF; 1000 units/ml) in combination with verapamil (50 microM) resulted in a further increase of class I antigens in the cells. The expressions of c-myc oncogene in K562 cells were not changed when the cells were treated with rIFN-gamma (600 units/ml) or verapamil (50 microM), either alone or in combination. These results indicate that verapamil synergistically interacts with rIFN-gamma on the class I antigen induction in K562 cells irrespective of c-myc gene expression and that class I antigen induction in this cell line may not be relevant to calcium influx triggered by IFN-gamma.

Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Antibodies, Monoclonal; Blotting, Northern; Calcimycin; Calmodulin; Cell Line; Egtazic Acid; Genes, MHC Class I; Genes, myc; Histocompatibility Antigens Class I; Humans; Interferon-gamma; Isoquinolines; Kinetics; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Recombinant Proteins; RNA, Neoplasm; Signal Transduction; Sulfonamides; Tumor Necrosis Factor-alpha; Verapamil

Leukotriene (LT) formation was studied in ionophore A23187-stimulated white blood cell (WBC) preparations from patients with chronic myelogenous leukaemia (CML; n = 14), polycythaemia vera (PV; n = 10) and two control groups consisting of patients with non-malignant inflammatory disease (n = 4) and normal healthy donors (n = 25). The synthesized products were identified and quantitated using high-performance liquid chromatography combined with computerized UV-spectroscopy. White blood cell preparations from the CML patients produced more LTC4 (40.2 +/- 7.9 pmol/10(6) WBC, mean +/- SEM) than WBC from the healthy donors (9.0 +/- 1.8), P less than 0.0005. In contrast, the formation of LTB4 was normal and there was no increase in the total leukotriene synthesis (the sum of LTC4, LTB4, 20-OH-LTB4 and the delta 6-trans-isomers of LTB4). The ratio between leukotrienes C4 and B4 was strongly elevated in the CML group; 1.67 +/- 0.25 v. 0.37 +/- 0.07 in the controls, P less than 0.0005. No significant correlation was observed between the levels of LTC4 and the number of known LTC4 producing cells (such as monocytes, eosinophils and basophils) in the CML WBC preparations. In contrast, a correlation was found between the sum of neutrophilic granulocytes and metamyelocytes in these suspensions and the amount of LTB4 formed; r = 0.600, P less than 0.05. A number of other laboratory or clinical variables of the CML patients (including total white blood cell and platelet counts, differential counts, previous cytotoxic treatment, time from diagnosis, time from last treatment, post study survival and age) did not significantly correlate with the formation of leukotrienes. No abnormality in the production of LTB4 or LTC4 was observed in granulocyte and WBC preparations from the patients with polycythaemia vera and non-malignant inflammatory disease, respectively. The results indicate a selectively increased LTC4 producing capacity in CML.

Topics: Adult; Aged; Blood Cell Count; Calcimycin; Cells, Cultured; Chromatography, High Pressure Liquid; Female; Granulocytes; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocytes; Male; Middle Aged; Polycythemia Vera; SRS-A

A sensitive gas chromatography-mass spectrometric method was used to measure the generation in whole blood of leukotriene B4 (LTB4), a potent stimulator of neutrophil chemotaxis, in eight patients with chronic granulocytic leukaemia (CGL) and 12 healthy controls. LTB4 was detectable in unstimulated samples from all the patients (mean 194 (70 SEM) pg/ml), and the capacity for LTB4 production after stimulation with calcium ionophore (A23187) was similar in patients (32.1 (11) ng/10(6) leucocytes) and controls (38.1 (4) ng/10(6) leucocytes). In response to stimuli which induce neutrophil activation, LTB4 production was significantly greater in the patients than in controls: 35.6 (13) v 13.0 (3) ng/ml, p less than 0.05 (f-met-leu-phe); and 42.4 (16) v 14.7 (4) ng/ml, p less than 0.02 (opsonised zymosan). Anti-IgE stimulated considerably more LTB4 production in patients with CGL than in controls (3.86 (1.6) v 0.83 (0.43) ng/ml; p less than 0.005) and this correlated significantly (p less than 0.05) with the basophil count. Neutrophil chemotaxis to LTB4, however, was significantly impaired in the patients with CGL even at the highest concentration of LTB4 (10(-5) M). Chemotaxis to f-met-leu-phe, phagocytosis, and bacterial killing were normal. Thus although LTB4 synthesis is normal or even enhanced in patients with CGL, specific defects in LTB4-mediated responses may contribute to neutrophil dysfunction in this disease.

Topics: Adult; Aged; Antibodies, Anti-Idiotypic; Calcimycin; Chemotaxis, Leukocyte; Humans; Immunoglobulin E; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukotriene B4; Male; Middle Aged; N-Formylmethionine Leucyl-Phenylalanine; Neutrophils; Phagocytosis

The production of leukotrienes (LT) in peripheral blood leukocyte preparations from 9 patients with chronic myelogenous leukemia (CML) and 9 healthy controls was studied. Leukotriene generation was stimulated by the calcium ionophore A 23187 (1 mumol). Lipoxygenase products were separated and identified using a high performance liquid chromatography (HPLC) technique and computerized spectrophotometry. Leukotriene C4 (LTC4) was formed in significantly larger amounts by cells from the CML patients than cells from the controls; 14.4 +/- 4.3 pmol per 10(6) nucleated cells (mean +/- SE) and 4.0 +/- 1.2 pmol respectively (p less than 0.05). Seven of the 9 patients but none of the controls synthesized equal or higher amounts of LTC4 than LTB4. A highly significant difference in mean values of LTC4/(LTB4 + 20-OH-LTB4) ratios was observed; CML 0.69 +/- 0.08 versus controls 0.12 +/- 0.02, p less than 0.001. These findings suggest an increased LTC4 synthase activity in CML cells. In earlier studies we have found a decreased 12-lipoxygenase activity in CML bone marrow cells.

Topics: Calcimycin; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocytes; Leukotriene B4; SRS-A